title: Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.
abstract: The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody rituximab. To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20.
  
  
  METHODS
  Two recombinant anti-CD20 rituximab fragments, a minibody (scFv-C(H)3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were generated. Both fragments were radiolabeled with (124)I, and the minibody was additionally labeled with (64)Cu (radiometal) after conjugation to 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). The radioiodinated fragments and the radiometal-labeled minibody were evaluated in mice as small-animal PET imaging agents for the in vivo imaging of human CD20-expressing lymphomas.
  
  
  RESULTS
  Rapid and specific localization to CD20-positive tumors was observed with the radioiodinated fragments. However, the tumor uptake levels and blood activities differed, resulting in different levels of contrast in the images. The better candidate was the minibody, with superior uptake (2-fold higher than that obtained with scFv-Fc) in CD20-positive tumors and low uptake in CD20-negative tumors. Ratios of CD20-positive tumors to CD20-negative tumors at 21 h were 7.0 +/- 3.1 (mean +/- SD) and 3.9 +/- 0.7 for the minibody and scFv-Fc, respectively. The ratio achieved with the (64)Cu-DOTA-minibody at 19 h was about 5-fold lower because of higher residual background activity in CD20-negative tumors.
  
  
  CONCLUSIONS
  A radioiodinated minibody and a radioiodinated scFv-Fc fragment produced excellent, high-contrast images in vivo. These new immunoPET agents may prove useful for imaging CD20-positive lymphomas in preclinical models and in humans with NHL.
authors.affiliation: Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA. tolafsen@mednet.ucla.edu
authors.forename: Tove
authors.initials: T
authors.lastname: Olafsen
authors.forename: David
authors.initials: D
authors.lastname: Betting
authors.forename: Vania E
authors.initials: VE
authors.lastname: Kenanova
authors.forename: Felix B
authors.initials: FB
authors.lastname: Salazar
authors.forename: Pat
authors.initials: P
authors.lastname: Clarke
authors.forename: Jonathan
authors.initials: J
authors.lastname: Said
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Raubitschek
authors.forename: John M
authors.initials: JM
authors.lastname: Timmerman
authors.forename: Anna M
authors.initials: AM
authors.lastname: Wu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007128:Immunoglobulin Fragments / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging* / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D049268:Positron-Emission Tomography / Q000379:methods* / Q000662:veterinary*; D019275:Radiopharmaceuticals / Q000276:immunology; D015203:Reproducibility of Results; D000069283:Rituximab; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007128:Immunoglobulin Fragments; D019275:Radiopharmaceuticals; D000069283:Rituximab
references.citation: Mol Immunol. 1993 Jan;30(1):105-8
references.pmid: 8417368
references.citation: Bioconjug Chem. 2001 Mar-Apr;12(2):320-4
references.pmid: 11312695
references.citation: Cancer. 2007 Aug 1;110(3):652-9
references.pmid: 17582800
references.citation: Blood. 2004 Nov 1;104(9):2635-42
references.pmid: 15226177
references.citation: Protein Eng Des Sel. 2004 May;17(5):481-9
references.pmid: 15316127
references.citation: Mol Imaging. 2003 Jul;2(3):131-7
references.pmid: 14649056
references.citation: Nucl Med Biol. 1997 Jul;24(5):451-9
references.pmid: 9290082
references.citation: J Clin Oncol. 1998 Aug;16(8):2825-33
references.pmid: 9704735
references.citation: Eur J Nucl Med. 1985;10(9-10):398-402
references.pmid: 4006981
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8495-500
references.pmid: 10880576
references.citation: Haematologica. 2006 Feb;91(2):176-83
references.pmid: 16461301
references.citation: J Immunol. 2008 Sep 15;181(6):4131-40
references.pmid: 18768870
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: Bioconjug Chem. 2001 Mar-Apr;12(2):220-8
references.pmid: 11312683
references.citation: Cancer Res. 1998 Sep 1;58(17):3905-8
references.pmid: 9731501
references.citation: J Clin Oncol. 1999 Dec;17(12):3793-803
references.pmid: 10577851
references.citation: Cancer Res. 1992 May 15;52(10):2907-15
references.pmid: 1581908
references.citation: Vox Sang. 2003 Apr;84(3):188-92
references.pmid: 12670367
references.citation: Cancer J. 2008 May-Jun;14(3):191-7
references.pmid: 18536559
references.citation: Nat Med. 2003 Mar;9(3):279-86
references.pmid: 12579196
references.citation: Cancer Res. 2005 Jul 1;65(13):5907-16
references.pmid: 15994969
references.citation: Cancer Res. 1996 Jul 1;56(13):3055-61
references.pmid: 8674062
references.citation: Biochemistry. 1995 Nov 14;34(45):14649-57
references.pmid: 7578107
references.citation: Cancer Res. 1992 Nov 15;52(22):6413-7
references.pmid: 1423290
references.citation: Expert Opin Biol Ther. 2007 Sep;7(9):1401-13
references.pmid: 17727329
references.citation: J Nucl Med. 2003 Dec;44(12):1962-9
references.pmid: 14660722
references.citation: J Immunol. 2007 Sep 1;179(5):3351-61
references.pmid: 17709552
references.citation: Cancer Res. 2005 Jan 15;65(2):622-31
references.pmid: 15695407
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Clin Cancer Res. 2008 Nov 15;14(22):7488-96
references.pmid: 19010866
references.citation: J Immunol. 1997 Mar 1;158(5):2211-7
references.pmid: 9036967
references.citation: Anal Biochem. 1987 Dec;167(2):290-4
references.pmid: 3442324
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4579-86
references.pmid: 18662969
references.citation: Cancer Res. 1990 Feb 1;50(3 Suppl):828s-834s
references.pmid: 2297729
references.citation: Eur J Immunol. 1977 Jul;7(7):413-7
references.pmid: 408154
references.citation: Protein Eng. 1993 Nov;6(8):989-95
references.pmid: 8309948
references.citation: Cancer. 2006 Jul 1;107(1):175-83
references.pmid: 16721817
references.citation: Nucl Med Biol. 1999 Nov;26(8):943-50
references.pmid: 10708309
references.citation: Cancer Res. 2007 Jan 15;67(2):718-26
references.pmid: 17234783
references.citation: J Clin Oncol. 2000 Mar;18(6):1316-23
references.pmid: 10715303
references.citation: Immunol Today. 1994 Sep;15(9):450-4
references.pmid: 7524522
references.citation: Nat Protoc. 2006;1(4):2048-60
references.pmid: 17487194
references.citation: Curr Dir Autoimmun. 2005;8:140-74
references.pmid: 15564720
references.citation: IEEE Trans Med Imaging. 1997 Apr;16(2):145-58
references.pmid: 9101324
references.citation: J Immunol. 2005 Jan 15;174(2):817-26
references.pmid: 15634903